News for Purple Biotech Ltd. (PPBT)

Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well posi

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drug

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific im

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (”œPurple Biotech” or the ”œCompany”) (NASDAQ/TASE: PPBT), a clinical-stage comp

ATAI Life Sciences N.V. (ATAI) saw its stock price fall by 5.03%, trading at $1.61 per share with a volume of 689,255 shares. The stock's turnover rate was 0.41

Agenus Inc. (AGEN), a biotechnology company, saw its stock price plummet by 5.50%, trading at $3.53 per share with a trading volume of 480,929 shares. The compa

Purple Biotech Ltd. (PPBT), a drug maker focused on tumor immune evasion and drug resistance, on Tuesday announced a registered direct offering of 472,668 of American Depositary Shares or ADSs at $6 per ADS.

**media[482178]**

ATAI Life Sciences N.V. (ATAI), a clinical-stage biopharmaceutical company, experienced a significant stock price drop of 5.62%, now trading at $1.68 per share

Editas Medicine, Inc. (EDIT) experienced a significant stock drop of 5.13%, trading at $2.13 with a volume of 1.33438 million shares. The turnover rate was 1.62

Capricor Therapeutics, Inc. (CAPR) saw a notable stock increase of 5.04%, reaching $19.97 per share. The trading volume was approximately 991,132 shares, with a

Purple Biotech Ltd. (PPBT), a clinical-stage biotechnology company, Monday announced positive final data from the Phase 2 study of its lead drug CM24 in pancreatic cancer.

Shares of Exicure, Inc. XCUR rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq c...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

DelveInsight’s pancreatic ductal adenocarcinoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies...

REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X ...

Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company.